← Eichor
Study identifier: NCT05005793 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients

Condition: Metabolic Acidosis · Kidney Transplant; Complications · Vascular Diseases  ·  Sponsor: University of Colorado, Denver

PhasePhase 4
Planned participants120
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Lower serum bicarbonate levels, even within the normal laboratory range, in kidney transplant recipients (KTRs) are associated with an increased risk of graft loss, cardiovascular events and mortality. Because acid retention is common in KTRs, it is plausible that alkali therapy in KTRs may also result in improved vascular and graft function. The investigators will perform a randomized, double-blinded, placebo-controlled, 12 month study in 120 KTRs to examine the effect of sodium bicarbonate therapy on surrogate markers of CVD and graft function. The overall hypothesis is that treatment with bicarbonate will improve indicators of vascular and graft function in KTRs by decreasing complement activation.

This description comes directly from the study's public registry record.

Talk to the study team

Jessica Kendrick, MD MPH  ·  3037244837  ·  jessica.kendrick@ucdenver.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of ColoradoAurora, Colorado, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05005793